BridgeBio Pharma, Inc. SEC filings BBIO
BridgeBio Pharma, Inc. has 833 filings in SEC EDGAR's recent list, going back to Jun 19, 2018. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| CT ORDER | Filing | Jul 18, 2023 | — |
| 425 | Filing | Jan 13, 2021 | — |
| 425 | 8-k | Jan 12, 2021 | — |
| 425 | Filing | Jan 4, 2021 | — |
| EFFECT | Filing | Dec 15, 2020 | — |
| CORRESP | Letter to the SEC | Dec 11, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2020 | — |
| CORRESP | Letter to the SEC | Nov 6, 2020 | — |
| 425 | 8-k | Oct 6, 2020 | — |
| 425 | Filing | Oct 6, 2020 | — |
| 425 | 8-k | Oct 5, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 27, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 7, 2020 | — |
| CERT | Filing | Jun 27, 2019 | — |
| EFFECT | Filing | Jun 26, 2019 | — |
| 8-A12B | Filing | Jun 26, 2019 | — |
| CORRESP | Letter to the SEC | Jun 25, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2019 | — |
| CORRESP | Letter to the SEC | Jun 24, 2019 | — |
| CORRESP | Letter to the SEC | Jun 24, 2019 | — |
| CORRESP | Letter to the SEC | Jun 11, 2019 | — |
| CORRESP | Letter to the SEC | Jun 11, 2019 | — |
| SEC STAFF LETTER | Filing | May 30, 2019 | — |
| UPLOAD | Letter from the SEC | May 30, 2019 | — |
| CORRESP | Letter to the SEC | May 24, 2019 | — |
| UPLOAD | Letter from the SEC | May 22, 2019 | — |
| DRSLTR | Filing | May 16, 2019 | — |
| DRS/A | Filing | May 16, 2019 | — |
| SEC STAFF LETTER | Filing | May 13, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2019 | — |
| DRSLTR | Filing | Apr 16, 2019 | — |
| DRS/A | Filing | Apr 16, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2019 | — |
| DRS | Filing | Feb 14, 2019 | — |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1743881
- Former names
- BridgeBio Pharma LLC (until May 16, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.